Code | CSB-RA225569A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IF | 1:20-1:200 |
The generation of the NFE2L2 recombinant monoclonal antibody involves a meticulous and well-defined process to ensure its high quality and specificity. It starts with the isolation of B cells from the spleen of an immunized animal, where the synthesized peptide derived from human Nrf2 is used as the immunogen. RNA is extracted from the B cells and converted into cDNA through reverse transcription. The NFE2L2 antibody genes are then amplified using specific primers designed for the antibody constant regions and inserted into an expression vector. The vector is introduced into host cells via transfection, enabling the production of the NFE2L2 recombinant monoclonal antibody. After a suitable incubation period, the antibody is collected from the cell culture supernatant and subjected to meticulous purification using affinity chromatography. This ensures the isolation of a highly purified form of the NFE2L2 recombinant monoclonal antibody suitable for various applications. Rigorous characterization assays, including ELISA and IF analysis, are performed to confirm the antibody's specificity and functionality in detecting human NFE2L2 protein. The stringent production process guarantees the development of a reliable and effective NFE2L2 recombinant monoclonal antibody, which serves as a valuable tool in diverse research related to NFE2L2.
Applications : Immunoblotting
Sample type: cells
Review: immunoblotting revealed that IL- 1β stimulation reduced the mRNA and protein levels of the anti-oxidative factors Nrf2, HO-1, NQO-1, SOD1, and SOD2,but kaempferol only partially mitigated IL-1-β induced oxidative changes.
By Anonymous